GSK migraine combo is Trexima
Executive Summary
GlaxoSmithKline/Pozen's acute migraine therapy combining Imitrex and naproxen will be marketed under the proposed brand name Trexima. Companies have commenced Phase III studies on the sumatriptan/naproxen fixed-dose combination and expect to submit an NDA in the second half of 2005. GSK and Pozen signed the development agreement in June 2003...